Scimago Lab
powered by Scopus
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


eISSN: 1643-3750

Get your full text copy in PDF

Whole-heart coronary magnetic resonance angiography with MS-325 (Gadofosveset)

Sebastian Kelle, Thomas Thouet, Tarinee Tangcharoen, Kai Nassenstein, Amedeo Chiribiri, Ingo Paetsch, Bernhard Schnackenburg, Jorg Barkhausen, Eckart Fleck, Eike Nagel

Med Sci Monit 2007; 13(11): CR469-474

ID: 512887

Background:    Magnetic resonance coronary angiography (MRCA) is limited by a low signal-to-noise-ratio (SNR), low spatial resolution, and limited coverage of the coronary artery tree. These aspects might be significantly improved by intravascular contrast agents. The aim of the study was to evaluate the feasibility of whole-heart contrast-enhanced MRCA using the intravascular contrast agent gadofosveset, formerly known as MS-325.
    Material/Methods:    Free-breathing navigator-gated MRCA using a single 3D volume with transversal slice orientation before and after injection of MS-325 (0.05 mmol/kg body-weight) was performed in 17 volunteers (6 men, aged 30±8 years). Signal intensities from the myocardium and left ventricular blood were assessed for non-enhanced and contrast-enhanced images. Signal-to-noise ratio of blood and contrast-to-noise ratios (CNR) were calculated. Image quality (0: no visualization, 1: nondiagnostic, 2: moderate, 3: good, 4: excellent) and MR angiograms (15-segment model following AHA/ACC guidelines) were evaluated. Visible vessel length and vessel sharpness were measured and visible coronary artery segments assessed.
    Results:    MR coronary artery imaging using MS-325 was successfully performed in 16 volunteers. One volunteer was excluded from the analysis because of trigger problems. SNR did not improve significantly after administration of MS-325 (14.1 vs. 14.6, p=NS), but CNR did (8.03 vs. 12.73, p<0.001). Image quality increased with MS-325 from 2.5±0.4 to 2.8±0.3 (p<0.05). Overall vessel length and vessel sharpness improved significantly after MS-325 administration (p<0.05).
    Conclusions:    Whole-heart coronary MRA with the intravascular contrast agent MS-325 enables significant improvement in CNR, blood-myocardial contrast, image quality, visible vessel length, and vessel sharpness over non-contrast MRCA.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree